Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 3/20 | 0.52 |
| ▸ | ACE | P12821 | 2/20 | 0.52 |
| ▸ | CALCRL | Q16602 | 2/20 | 0.52 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.51 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.50 |
| ▸ | MMP2 | P08253 | 1/20 | 0.49 |
| ▸ | MMP8 | P22894 | 1/20 | 0.49 |
| ▸ | MMP12 | P39900 | 1/20 | 0.49 |
| ▸ | MMP13 | P45452 | 1/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.49 |
| ▸ | HPGDS | O60760 | 1/20 | 0.48 |
| ▸ | CTSL | P07711 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14598297 | 1.00 | MME (0.52) | MMEACECALCRLSSTR5ROCK2 | |
| SCHEMBL14122758 | 0.86 | MMP12 (0.64) | MMECALCRLSSTR5ROCK2MMP2 | |
| SCHEMBL14122875 | 0.86 | MMP12 (0.64) | MMECALCRLSSTR5ROCK2MMP2 | |
| SCHEMBL6868685 | 0.86 | MMP12 (0.64) | MMECALCRLSSTR5ROCK2MMP2 | |
| SCHEMBL14122164 | 0.86 | MMP12 (0.64) | MMECALCRLSSTR5ROCK2MMP2 | |
| SCHEMBL19112073 | 0.86 | MMP12 (0.64) | MMECALCRLSSTR5ROCK2MMP2 | |
| SCHEMBL6868588 | 0.86 | MMP12 (0.64) | MMECALCRLSSTR5ROCK2MMP2 | |
| SCHEMBL6869090 | 0.86 | MMP12 (0.64) | MMECALCRLSSTR5ROCK2MMP2 | |
| SCHEMBL14598306 | 0.86 | NPY4R (0.62) | — | |
| SCHEMBL14598296 | 0.86 | NPY4R (0.62) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070004644-A1 | Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia | SIRCAR JAGADISH C | 2007-01-04 | — | — | US | disclosed |
| US-20070004644-A1 | Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia | SIRCAR JAGADISH C | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004644-A1 | Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia | CETP, LDLR, NPC1L1 | MME 2615/4885ACE 2658/4885CALCRL 1395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.